FENC · Fennec Pharmaceuticals Inc. · Earnings Call Transcripts & Audio
$10.65
-0.15 (-1.39%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$371.89M
Shares
35.07M
Volume · Sep 30
149.21K
Avg daily vol (3M)
197.63K
Fennec Pharmaceuticals Inc. Earnings Call Transcripts
Quarterly earnings calls for Fennec Pharmaceuticals Inc. (FENC), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
·
$1.68M
−$6.05M
'23 Q1
23-05-11
·
$3.33M
−$5.44M
'23 Q2
23-08-03
·
$6.51M
−$1.87M
'23 Q3
23-11-06
·
$9.73M
−$2.68M
'23 Q4
24-03-21
▲1413.2%
$25.38M
$12.84M
'24 Q1
24-05-14
▲118.4%
$7.26M
−$5.55M
'24 Q2
24-08-13
▲7%
$6.97M
−$5.74M
'24 Q3
24-11-07
▼18.6%
$7.92M
−$1.99M
'24 Q4
25-03-10
▼65.5%
$8.75M
−$1.17M
'25 Q1
25-05-13
▲32.9%
$9.65M
−$3.15M
'25 Q2
25-08-14
▲73.8%
$13.78M
−$4.79M
'25 Q4
26-03-24
▲72.6%
$15.11M
$201,000
'26 Q1
26-05-14
LATEST
▲85.2%
$17.87M
$1.97M
'26 Q2
26-08-11
Conference
Investor event
2026-09-15
Fennec Pharmaceuticals Inc. (FENC) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-15
Fennec Pharmaceuticals Inc. (FENC) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-11
Fennec Pharmaceuticals Inc. (FENC) Q2 2026 Earnings Call Transcript
Confident tone
Investigator-sponsored studies (ISTs) and label expansion
Commercial growth and demand momentum
Japan / Asia-Pacific partnership and launch planning
Revenue
$17.87M
▲ 85.2% YoY Diluted EPS
$0.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-05-19
Fennec Pharmaceuticals Inc. (FENC) May 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-19
Fennec Pharmaceuticals Inc. (FENC) May 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-14
Fennec Pharmaceuticals Inc. (FENC) Q1 2026 Earnings Call Transcript
Confident tone
PEDMARK label expansion and clinical evidence
Pipeline expansion into new tumor types
Commercial execution and field force expansion
Revenue
$15.11M
▲ 72.6% YoY Diluted EPS
$0.01
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-24
Fennec Pharmaceuticals Inc. (FENC) Q4 2025 Earnings Call
Confident tone
Pedmark label and lifecycle
Label expansion opportunities
Financial performance and outlook
Revenue
$13.78M*
▲ 73.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q2
2025-08-14
Fennec Pharmaceuticals Inc. (FENC) Q2 2025 Earnings Call Transcript
Confident tone
Revenue Growth and Commercial Performance
PEDMARK Adoption and Standard of Care
International Expansion via Norgine
Revenue
$9.65M
▲ 32.9% YoY Diluted EPS
$-0.11
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Fennec Pharmaceuticals Inc. (FENC) Q1 2025 Earnings Call Transcript
Confident tone
AYA (adolescent and young adult) market expansion
European launch via Norgine partnership (PEDMARQSI)
Fennec HEARS patient support program
Revenue
$8.75M
▼ 65.5% YoY Diluted EPS
$-0.04
▼ 109.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-10
Fennec Pharmaceuticals Inc. (FENC) Q4 2024 Earnings Call Transcript
Confident tone
AYA market expansion
European launch via Norgine
NCCN compendia and guidelines
Revenue
$7.92M*
▼ 18.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Fennec Pharmaceuticals Inc. (FENC) Q3 2024 Earnings Call Transcript
Confident tone
PEDMARK commercial execution and five strategic pillars
AYA (Adolescent and Young Adult) market expansion
Pediatric and academic center adoption vs. compounding
Revenue
$6.97M
▲ 7% YoY Diluted EPS
$-0.21
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
Fennec Pharmaceuticals Inc. (FENC) Q2 2024 Earnings Call Transcript
Confident tone
PEDMARK commercial launch
Norgine partnership (PEDMARQSI ex-U.S.)
Leadership transition / new CEO
Revenue
$7.26M
▲ 118.4% YoY Diluted EPS
$-0.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
Fennec Pharmaceuticals Inc. (FENC) Q1 2024 Earnings Call Transcript
Positive tone
PEDMARK U.S. commercial launch challenges
Norgine ex-U.S. licensing partnership
FDA safety communication on substitution
Revenue
$25.38M
▲ 1413.2% YoY Diluted EPS
$0.41
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-21
Fennec Pharmaceuticals Inc. (FENC) Q4 2023 Earnings Call Transcript
Confident tone
PEDMARK US commercial launch
Norgine licensing deal for Europe
FDA communication on sodium thiosulfate substitutions
Revenue
$9.73M*
Gross margin
93.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-06
Fennec Pharmaceuticals Inc. (FENC) Q3 2023 Earnings Call Transcript
Revenue
$6.51M
Diluted EPS
$-0.07
Gross margin
94.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Fennec Pharmaceuticals Inc. (FENC) Q2 2023 Earnings Call Transcript
Revenue
$3.33M
Diluted EPS
$-0.21
Gross margin
95.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Fennec Pharmaceuticals Inc. (FENC) Q1 2023 Earnings Call Transcript
Revenue
$1.68M
Diluted EPS
$-0.23
Gross margin
94.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–17 of 17 earnings calls